What You Should Know:
Niterra, a global leader in diverse industries, today announced its participation in a $10M convertible debt financing round for Imbed Biosciences, Inc. (Imbed), a rising star in the field of tissue engineering.
– This strategic investment marks Niterra’s commitment to supporting innovative solutions that improve patient quality of life and aligns perfectly with its transformation towards non-internal combustion engine businesses.
Revolutionizing Wound Care with Microlyte® Technology
Imbed has pioneered a revolutionary wound care technology called Microlyte®, the world’s first fully-synthetic and antimicrobial wound matrix. This FDA-cleared biocompatible polymer matrix creates a healing environment conducive to tissue growth while suppressing harmful microbes and biofilms. Clinical trials have demonstrated the matrix’s ability to jump-start healing in stagnant chronic wounds, leading to faster recovery with reduced infection risk and improved patient outcomes.
“People with slow-healing wounds face immense risks,” explains Ankit Agarwal, PhD, co-founder and chief scientific and quality officer at Imbed. “Our patented Microlyte® technology addresses this critical need by offering a safe and effective solution that has already helped over 100,000 patients in the past year. This investment from Niterra allows us to accelerate our commercial reach and develop new solutions to help even more people.”
Growth of Global Advanced Wound Care Market
The global advanced wound care market is projected to reach a staggering $18.7 billion by 2027, with chronic wounds impacting millions worldwide. Imbed’s innovative approach positions the company to capture a significant share of this market, further establishing itself as a leader in the field. The recent funding will be used to scale commercial operations, fuel research and development, and expand sales channels.
